Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial.

ABSTRACT:

Background

Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity via its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resulting in increased insulin resistance. In a randomised controlled trial (RCT) of zoledronic acid versus placebo in men commencing extended-duration ADT, we aimed to examine the effects on fat mass and glucose metabolism. We hypothesised that zoledronic acid, which reduces osteocalcin concentrations, would worsen ADT-induced insulin resistance.

Methods

This was a prespecified secondary analysis of an RCT designed to evaluate the effects of zoledronic acid on bone microarchite

SUBMITTER: Cheung AS 

PROVIDER: S-EPMC8111529 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature